TuHURA Biosciences Reports Board Changes and Compensation Updates
Ticker: HURA · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1498382
Sentiment: neutral
Topics: board-changes, executive-compensation, filing
TL;DR
TuHURA Biosciences shakes up its board and compensation plans.
AI Summary
TuHURA Biosciences, Inc. announced on November 12, 2024, a change in its board of directors. Specifically, the company reported the departure of directors and the election of new directors, along with updates to executive compensation arrangements. The filing also includes financial statements and exhibits.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- November 12, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of Incorporation
- 10500 University Dr., Suite 110 (address) — Business and Mail Address
FAQ
What specific changes were made to the board of directors at TuHURA Biosciences?
The filing indicates a departure of directors and the election of new directors, though specific names are not detailed in this summary section.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 12, 2024.
What is the state of incorporation for TuHURA Biosciences?
TuHURA Biosciences is incorporated in Nevada.
What other items are included in this 8-K filing besides director changes?
The filing also includes information on compensatory arrangements of certain officers and financial statements and exhibits.
What is the business address of TuHURA Biosciences?
The business address is 10500 University Dr., Suite 110, Tampa, FL 33612.
Filing Stats: 727 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-11-15 17:00:03
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
- $499,000 — n Dearborn, Chief Financial Officer, to $499,000 and $375,000, respectively, with such i
- $375,000 — hief Financial Officer, to $499,000 and $375,000, respectively, with such increase to be
- $4.94 — 019;s common stock on the grant date of $4.94. Each Stock Option Award has a term of
Filing Documents
- hura-20241115.htm (8-K) — 41KB
- hura-ex10_1.htm (EX-10.1) — 49KB
- 0000950170-24-127673.txt ( ) — 91KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. 10.1 Form of Stock Option Agreement under 2024 Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: November 15, 2024 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer